PRIMA1 and breast carcinoma: We initially showed, in animal models, that PRIMA-1 and APR-246 effectively inhibit the development of tumors in xenografts derived from human breast cancer cells; their activity was bolstered by the concomitant administration of 2aG4, an antibody that targets tumor blood vessels.